Tempus AI product for pulmonary hypertension detection gets FDA clearance

Tempus has received clearance from the United States Food and Drug Administration (FDA) for a new AI product. This product is designed to detect signs of pulmonary hypertension using standard electrocardiograms (ECGs). The clearance marks a significant step in leveraging AI for cardiovascular diagnostics. AI

IMPACT This AI product's FDA clearance could pave the way for broader adoption of AI in cardiovascular diagnostics, potentially improving early detection of conditions like pulmonary hypertension.

RANK_REASON FDA clearance for a specific AI product.

Read on Mastodon — sigmoid.social →

• European Center for Geodynamics and Seismology
• pulmonary hypertension
• TEMPUS
• United States Food and Drug Administration

• product
• safety

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →